Form 4: Heidi Fields Acquires Phathom Pharmaceuticals Stock

Heidi Fields, a Director at Phathom Pharmaceuticals, Inc., acquired 24,122 shares of common stock through Restricted Stock Units on May 19, 2026.

Summary

• Heidi Fields, a Director of Phathom Pharmaceuticals, Inc., acquired 24,122 shares of common stock.
• The acquisition was made through Restricted Stock Units (RSUs) granted on May 19, 2026, under the company's Non-Employee Director Compensation Program.
• These RSUs will vest on the first anniversary of the grant date or the next annual stockholder meeting, provided Ms. Fields continues to serve on the Board.
• Each RSU represents a contingent right to receive one share of common stock.
• Following this transaction, Ms. Fields beneficially owns 54,122 shares of common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it represents a standard compensation grant and acquisition by a director, signaling continued engagement rather than a significant new investment or divestment.

Positives

• Director acquisition of company stock can signal confidence in the company's future prospects.
• The acquisition of 24,122 shares by a director indicates continued commitment to the company.

Future Outlook

The Restricted Stock Units are subject to vesting conditions tied to continued service and specific future dates, indicating a long-term incentive structure for the director.

Industry Context

StockSavvy.ai notes that insider stock acquisitions, particularly by directors, are common within the biopharmaceutical sector as a means of aligning executive interests with shareholder value and demonstrating commitment during critical development phases.

Stakeholder Impact

• Shareholders: The acquisition by a director may be viewed positively, suggesting confidence in the company's future performance. However, it is a standard compensation event.
• Employees: The compensation structure for directors is part of the overall governance framework.
• Management: Reinforces the alignment of director incentives with shareholder interests.

Next Steps

• Vesting of Restricted Stock Units on the first anniversary of the grant date or the next annual stockholder meeting, contingent on continued service.
• Potential future transactions by Heidi Fields related to her beneficial ownership of Phathom Pharmaceuticals stock.

Key Dates

Keywords

Phathom Pharmaceuticals, PHAT, Form 4, Insider Trading, Stock Acquisition, Restricted Stock Units, Director Compensation, SEC Filing